共 139 条
[1]
Locke GR(2002)Natural history of nonerosive reflux disease Gastroenterol Clin North Am 31 S59-S66
[2]
DeVault KR(2005)Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease Am J Gastroenterol 100 190-200
[3]
Castell DO(1992)Medical treatment of reflux esophagitis Hepatogastroenterology 39 322-324
[4]
Olbe L(1995)Critical issues in the management of gastroesophageal reflux disease Eur J Gastroenterol Hepatol 7 577-586
[5]
Lundell L(1997)Gastroesophageal reflux Ther Umsch 54 611-616
[6]
Freston JW(1997)Long-term management of gastroesophageal reflux disease and its complications Am J Gastroenterol 92 30S-35S
[7]
Malagelada JR(1998)Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors Am J Gastroenterol 93 763-767
[8]
Petersen H(2011)A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals J Pharmacol Exp Ther 337 797-804
[9]
Schwizer W(2008)A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease Am J Gastroenterol 103 20-26
[10]
Fried M(2014)Tu1052 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis Gastroenterology 146 S-738-784